share_log

Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22

Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22

武田制药21财年核心利润增长1%，预计22财年增长势头
Benzinga Real-time News ·  2022/05/11 06:34
  • Takeda Pharmaceutical Company Limited (NYSE:TAK) reported a fiscal 2021 core net profit of ¥663.7 billion, an increase of 1.3% from the prior year. Core earnings per share reached ¥425, up 1.2%.
  • FY21 net profit declined 38.8% to ¥230.1 billion.
  • Fiscal 2021 core revenue was ¥3.42 trillion, an underlying increase of 7.4%.
  • Gastroenterology sales reached ¥875.7 billion, up 7% on an underlying basis driven by gut-selective Entyvio and anti-acid therapy Takecab. Takeda is no longer expecting entry of biosimilars upon loss of data exclusivity.
  • Also See: Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients.
  • Rare Diseases sales decreased 1% to ¥611.2 billion in reported revenue, impacted by a decline in line with expectations in Rare Hematology due to intensified competition. 
  • Plasma Derived Therapy Immunology segment revenues increased 14% to ¥507.0 billion, and Oncology sales grew 8% to ¥468.7 billion.
  • Neuroscience sales were up 10% to ¥482.3 billion.
  • Guidance: Takeda forecasts FY22 core sales of ¥3.69 trillion, up 7.9%.
  • In FY2022, Takeda expects continued revenue growth. Core operating profit is expected to reach ¥1.1 trillion, mainly driven by business momentum.
  • Price Action: TAK shares closed 1.33% higher at $14.52 on Tuesday.
  • 武田药品株式会社(纽约证券交易所股票代码：TAK)公布2021财年核心净利润为人民币6637亿元，同比增长1.3%。每股核心收益达到425元，增长1.2%。
  • 2011财年净利润下降38.8%，至人民币2301亿元。
  • 2021财年核心收入3.42万亿元，潜在增长7.4%。
  • 胃肠科销售额达到8,757亿元，在肠道选择性Entyvio和抗酸疗法Takecab的推动下，基本销售额增长7%。武田不再期待在失去数据排他性后进入生物仿制药。
  • 另请参阅： 武田公司的Maribavir降低了移植后感染患者的住院率和住院时间.
  • 罕见疾病销售额下降1%，至人民币6,112亿元，受竞争加剧导致罕见血液病销售额下降符合预期的影响。
  • 血浆衍生疗法免疫部门的收入增长了14%，达到人民币5070亿元，肿瘤学的销售额增长了8%，达到人民币4687亿元。
  • 神经科学的销售额增长了10%，达到人民币4823亿元。
  • 指导意见：武田预计，2012财年核心销售额为人民币3.69万亿元，增长7.9%。
  • 武田预计，在2022财年，收入将继续增长。预计核心营业利润将达到1.1万亿元，主要受业务动能推动。
  • 价格行动：德意志银行股价周二收高1.33%，报14.52美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发